Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 2/20 | 0.43 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ACACB | O00763 | 4/20 | 0.39 |
| ▸ | NPY5R | Q15761 | 3/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.38 |
| ▸ | OGA | O60502 | 1/20 | 0.38 |
| ▸ | RET | P07949 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3662351 | 0.85 | AAK1 (0.46) | JAK3MCHR1HRH3KDM4EABL1 | |
| SCHEMBL3811671 | 0.82 | CCR5 (0.48) | JAK3MCHR1HRH3KDM4EABL1 | |
| SCHEMBL3669359 | 0.81 | KDM4E (0.45) | MCHR1KDM4EABL1LMNAMAP4K4 | |
| SCHEMBL3666955 | 0.81 | CHRM4 (0.45) | MCHR1HRH3KDM4EABL1LMNA | |
| SCHEMBL3666603 | 0.80 | KDM4E (0.42) | JAK3MCHR1HRH3KDM4EABL1 | |
| SCHEMBL3666820 | 0.80 | JAK2 (0.42) | MCHR1HRH3KDM4EABL1LMNA | |
| SCHEMBL3668764 | 0.79 | KDM4E (0.49) | MCHR1HRH3KDM4EABL1LMNA | |
| SCHEMBL3663778 | 0.79 | KDM4E (0.40) | JAK3MCHR1KDM4EABL1LMNA | |
| SCHEMBL3665883 | 0.78 | AAK1 (0.53) | JAK3MCHR1HRH3ACACBCHRM4 | |
| SCHEMBL3668424 | 0.78 | JAK2 (0.51) | JAK3MCHR1KDM4EABL1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2155687-A1 | DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | Via Pharmaceuticals, Inc. (US) | 2010-02-24 | — | — | EP | disclosed |
| US-20090170864-A1 | Diacylglycerol Acyltransferase Inhibitors | MADRIGAL PHARMACEUTICALS, INC. | 2009-07-02 | — | — | US | disclosed |
| US-20090105273-A1 | Diacylglycerol Acyltransferase Inhibitors | MADRIGAL PHARMACEUTICALS, INC. | 2009-04-23 | — | — | US | disclosed |
| US-20090099201-A1 | Diacylglycerol Acyltransferase Inhibitors | VIA PHARMACEUTICALS, INC. | 2009-04-16 | — | — | US | disclosed |
| US-20090093497-A1 | Diacylglycerol Acyltransferase Inhibitors | MADRIGAL PHARMACEUTICALS, INC. | 2009-04-09 | — | — | US | disclosed |
| WO-2008141976-A1 | DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | VIA PHARMACEUTICALS, INC. (US) | 2008-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093497-A1 | Diacylglycerol Acyltransferase Inhibitors | DGAT2, DGAT1, LCAT | JAK3 4303/4885MCHR1 4616/4885HRH3 4353/4885 |
| US-20090170864-A1 | Diacylglycerol Acyltransferase Inhibitors | DGAT2, DGAT1, LCAT | JAK3 4303/4885MCHR1 4616/4885HRH3 4353/4885 |
| US-20090099201-A1 | Diacylglycerol Acyltransferase Inhibitors | DGAT2, DGAT1, LCAT | JAK3 4303/4885MCHR1 4616/4885HRH3 4353/4885 |
| US-20090105273-A1 | Diacylglycerol Acyltransferase Inhibitors | DGAT2, DGAT1, LCAT | JAK3 4303/4885MCHR1 4616/4885HRH3 4353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.